<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62853">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02287662</url>
  </required_header>
  <id_info>
    <org_study_id>TBD</org_study_id>
    <nct_id>NCT02287662</nct_id>
  </id_info>
  <brief_title>The Multidisciplinary, Multimodality, But Minimalist Approach to Transfemoral Transcatheter Aortic Valve Replacement</brief_title>
  <acronym>3MTAVR</acronym>
  <official_title>The Multidisciplinary, Multimodality, But Minimalist (3M) Approach to Transfemoral Transcatheter Aortic Valve Replacement (TAVR) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BC Centre for Improved Cardiovascular Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>BC Centre for Improved Cardiovascular Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to provide a rigorous assessment of the efficacy,
      feasibility and safety of the Vancouver 3M Clinical Pathway protocol in patients undergoing
      elective transfemoral TAVR with balloon expandable valves.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The composite of all-cause mortality, major stroke (disabling stroke) or life-threatening bleed.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The composite of all-cause mortality or major stroke (disabling stroke).</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Vancouver 3M Clinical Pathway</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Vancouver 3M Clinical Pathway utilizes objective anatomical and functional screening criteria as well as strict peri-procedural guidelines to determine if next day discharge home is appropriate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vancouver 3M Clinical Pathway</intervention_name>
    <arm_group_label>Vancouver 3M Clinical Pathway</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with severe symptomatic aortic stenosis undergoing elective transfemoral TAVR
        with a balloon expandable transcatheter heart valve

          1. Considered at increased surgical risk by the Multidisciplinary Heart Team.

          2. Informed written consent

        Exclusion Criteria:

          1. Non -cardiovascular co-morbidity reducing life expectancy to &lt; 3 years

          2. Any factor precluding 1 year follow-up

          3. Inadequate CT image acquisition to perform area-based annular CT sizing, exclude
             adverse root features, and determine a coaxial valve deployment angle (CT is not
             required for valve-in-valve procedures)

          4. Predicted inability to perform uncomplicated percutaneous vascular access and closure

          5. Iliofemoral diameter &lt; 6 mm for SAPIEN XT or &lt;5.5 mm for SAPIEN 3 (measured at or
             above the mid-femoral head)

          6. Inpatient (unless clinically stable, mobilizing at baseline, and primarily in
             hospital for logistical reasons.

          7. Significant communication barrier(s) that interfere with ability to follow
             peri-procedural and discharge instructions

          8. MMSE &lt; 24/30 (unless language barrier or limited formal education), 5-metre gait &gt; 7
             seconds (unless chronic mobility impairment not affecting ability to perform ADLs),
             and ADL &lt; 6/6

          9. Insufficient social support to facilitate next day discharge

         10. Airway unfavourable for emergent intubation

         11. Inability to lay supine without conscious sedation or general anesthetic

         12. Not receiving a balloon expandable transcathter heart valve
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A Wood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John A Webb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David A Wood, MD</last_name>
    <phone>604 875 5601</phone>
    <email>david.wood@vch.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shirley C Wong, PhD</last_name>
    <phone>604-682-2344</phone>
    <phone_ext>65676</phone_ext>
    <email>3M@icvhealth.ubc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Wood, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 29, 2016</lastchanged_date>
  <firstreceived_date>November 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcatheter Aortic Valve Replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
